Asad Abbas, MD
Ophthalmology · Baytown, TXNPI 1457354813
Payments from drug & device makers
What this record shows
15 manufacturers reported payments, led by Johnson & Johnson Vision Care, Inc. at 40.9% of the total. Reporting peaked in 2021 at $507 and has fallen 76.4% since, to $120 in 2025. That places this record below the midpoint for ophthalmology clinicians in TX, where the typical reported total is $1,835.
Across 28 payments — averaging $37.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Vision Care, Inc.$435
- AbbVie$178
- Alcon$107
- Amgen$82
- Bausch & Lomb, A Division Of Bausch Health US, LLC$54
- Glaukos Corporation$38
- plus $169 from 9 others
Across 7 payments — averaging $318.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$2K
What the payments were for
- Food & beverage$62859%
- Other$43541%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Vision Care, Inc. | 1 | $435 |
| AbbVie(2 entities) | 4 | $178 |
| Alcon | 6 | $107 |
| Amgen(2 entities) | 4 | $82 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $54 |
| Glaukos Corporation | 1 | $38 |
| Sight Sciences, Inc. | 1 | $26 |
| Novartis | 1 | $25 |
| Aerie Pharmaceuticals, Inc. | 1 | $23 |
| Dompe US, Inc. | 1 | $20 |
| Ocular Therapeutix, Inc. | 1 | $19 |
| Biotissue Holdings Inc. | 1 | $17 |
| Bausch & Lomb Americas Inc. | 1 | $16 |
| Rxsight Inc | 1 | $13 |
| Sun Pharmaceutical Industries Inc. | 1 | $11 |
How this compares
$1,063 in reported general payments places this provider in the 35th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 41 | $30,283 |
| LumiganBimatoprost | 61 | $22,264 |
| CombiganBrimonidine Tartrate/Timolol | 44 | $18,352 |
| XiidraLifitegrast | 19 | $18,343 |
| Prednisolone Acetate | 388 | $16,631 |
| Ketorolac Tromethamine | 374 | $10,094 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 57 | $9,598 |
| Latanoprost | 1,188 | $8,486 |
| MoxifloxacinMoxifloxacin Hcl | 336 | $7,800 |
| Cyclosporine | 14 | $7,537 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 470 | $6,260 |
| Brimonidine Tartrate | 314 | $4,849 |
| Brinzolamide | 17 | $2,557 |
| Timolol Maleate | 255 | $2,166 |
| Fluorometholone | 22 | $1,720 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $178 | $70,899146 claims |
| Bausch & Lomb Americas Inc.Xiidra | $16 | $18,34319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Baytown
- Michael SingerSan Antonio$1.8M
- Oluwatosin SmithDallas$1.5M
- Charles WykoffBellaire$1.5M
- John MichelettiHouston$916K
- Davinder GroverDallas$705K
- Christina WengHouston$676K
- Peter ChangHouston$656K
- Zaina Al-MohtasebHouston$636K
- Ashkan AbbeyDallas$559K
- Stephen SladeHouston$530K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.